key: cord-0986955-14tee5lz
authors: Agarwal, Manyoo A.; Ziaeian, Boback; Lavie, Carl J.; Fonarow, Gregg C.
title: Cardiovascular Disease in Hospitalizations With a Diagnosis of Coronavirus From Pre-COVID-19 Era in United States: National Analysis From 2016-2017
date: 2020-09-22
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.09.022
sha: 3e030c05d4c419502748392683a9b5e4c7fd01d3
doc_id: 986955
cord_uid: 14tee5lz

Objective To analyze the cardiovascular disease (CVD) burden in hospitalized patients with a diagnosis of coronavirus from pre-COVID-19 era in United States (US). Patients and Methods We identified adult hospitalizations with a diagnosis of coronavirus in a large US administrative database, National (Nationwide) Inpatient Sample (January 1, 2016 to December 3, 2017) to study patient demographics, clinical comorbidities and outcomes (in-hospital mortality and healthcare resource utilization) based upon presence or absence of CVD. Results A total of 21,300 adult hospitalizations with a diagnosis of coronavirus from 2016 to 2017 all across US were included in the final analysis; the mean age was 63.6 years, 51.8% were female and 74.7% public insurers. Among these, 11,930 hospitalizations (56.0%) had a diagnosis of CVD. Compared with those without CVD, hospitalizations with CVD were older (age, 70.1 vs. 55.4 years), had higher Charlson comorbidity score (2.5 vs. 1.6) and Elixhauser comorbidity index (4.3 vs. 2.4) (all p<.001). After multivariable risk adjustment, hospitalizations with CVD had higher mortality than those without CVD (5.3% vs. 1.5%; adjusted odds ratio = 2.0, 95% CI 1.2 to 3.4, p=.008). The mean length of stay (6.9 vs. 6.1 days, p=.003), hospital charges (78,377 vs. 66,538 US dollars, p=.002) and discharge disposition to nursing home was higher in those with CVD (24.6% vs. 12.9%, p<.001) when compared to no-CVD group. Conclusion: CVD was present in a significant proportion of hospitalizations with coronavirus in pre-COVID-19 era in US and was associated with higher risk of in-hospital mortality and healthcare resource utilization.

Coronavirus are the largest group of viruses; and since their discovery in 1960, several different strains have been associated with respiratory illnesses, such as human .21, B97.29 were used to identify our coronavirus study population. We followed the recommendations from the AHRQ for analysis using survey data such as using surveyspecific statements and utilizing patient-specific and hospital-specific discharge weights as done previously 9, 11 . Estimates were weighted, unless otherwise noted, to allow for nationally representative interpretations. We accounted for hospital-level clustering of patients and the sampling design. Given this is a publicly available, deidentified database, we obtained an institutional review board exemption from the University of California Los Angeles.

All patients with age >17 years with a diagnosis of coronavirus (in primary or secondary diagnosis field) were included in the study. NIS variables were used to identify patient's demographic characteristics, clinical comorbidities, length of stay (LOS), total charges (in USD) and discharge disposition (home, nursing home or similar ancillary services, morgue) 11 . ICD-10-CM or Clinical Classifications Software codes were used to define comorbidities (Supplemental Table 1 ). The hospitalization was J o u r n a l P r e -p r o o f classified as cardiovascular (CV) admission if CV-etiology related ICD diagnosis code was present in the primary diagnostic field as done previously 10 . The severity of comorbid conditions was studied using Deyo modification of Charlson comorbidity index (CCI), which contains 17 comorbid conditions with differential weights and the Elixhauser comorbidity index, which is a sum of the 29 Elixhauser comorbidity variables 12, 13 .

We defined CVD as the presence of one of the following: coronary artery disease (CAD), myocardial infarction (MI), heart failure (HF), sudden cardiac arrest, conduction disorders, cardiac dysrhythmias, cardiomyopathy, pulmonary heart disease, venous thromboembolic disorders, pericardial diseases, heart valve disorders and peripheral arterial disease (Supplemental Table 1 ).

We initially studied the characteristics: age, female, race, insurance, median socioeconomic status, Charlson comorbidity score, Elixhauser comorbidity index, clinical comorbidities [hypertension, hyperlipidemia, diabetes, obesity, chronic pulmonary disease (COPD), renal disease, liver disease, cancer, dementia, pneumonia, acute respiratory failure, shock, sepsis, human immunodeficiency virus, history of organ transplant, mechanical invasive ventilation] based upon the presence and absence of CVD (Table 1 and Supplemental Table 2 ). Then we studied the outcomes of in-hospital mortality and health care resource utilization (LOS, days; total charges, in USD; discharge to nursing home) ( Table 2) . We performed additional analysis for the outcome of in-hospital mortality a) by comparing those with a primary CV diagnosis vs. those with non-CV primary diagnosis b) by comparing those with systolic HF vs. those without systolic HF (Supplemental Table 3 ). For the outcomes of LOS and total charges, J o u r n a l P r e -p r o o f additional analysis was performed after excluding those who died before discharge (Supplemental Table 4 ).

Descriptive analyses were performed using mean [interquartile range (IQR)] and proportions (IQR) as appropriate. Pearson χ 2 tests was used to describe the characteristics of hospitalizations with and without CVD (Table 1) . Comparisons among continuous variables were made with the Student's t-test. Significance testing was performed with multivariable unconditional logistic regression with CVD as a categorical variable for the outcomes of in-hospital mortality and discharge to nursing home or similar facility. The influence of potential confounders was analyzed by incremental adjustments (Figure 1 ).

Model 1 was unadjusted. Model 2 adjusted for age groups, sex, race and insurance.

Model 3 adjusted for covariates included in Model 2 plus Charlson comorbidity score, Elixhauser comorbidity index and clinical comorbidities comorbidities (hypertension, hyperlipidemia, diabetes, obesity, chronic pulmonary disease, renal disease, cancer, liver disease, dementia). Model 4 (Supplemental Table 5 ) adjusted for all covariates in model 3 plus human immunodeficiency virus status, history of organ transplant, pneumonia, shock, acute respiratory failure, sepsis and mechanical invasive ventilation. We used multivariable Poisson regression analyses with robust SEs (using Model 4) to compare length of hospital stay and total charges per hospitalization ( Table 2) . We also performed a subgroup analysis to study the association of specific CVD with in-hospital mortality using events reported recently in corona virus literature by the presence of one of the following: acute MI, HF, pericardial diseases, myocarditis, acute pulmonary embolism, and sudden cardiac arrest 4, 6, 14, 15 (Supplemental Table 6 -8, Supplemental 

The overall in-hospital mortality was 3.6%, and presence of CVD was associated with higher risk of in-hospital mortality (5.3% vs. 1.5%; AOR = 2.0, 95% CI 1.2 to 3.4, p= .008) when compared with those without CVD (Table 2) . Also, those with primary CV diagnosis had similar in-hospital mortality when compared to those who had primary non-CV diagnosis (3.4% vs. 3.7%, p =0.807).

The mean LOS was 6.6 days with the mean hospital total charges of 73,137$ ( ], p <.001) was higher in those with CVD. However after adjustment for covariates, presence of CVD no longer had significant association with higher utilization of nursing or similar ancillary facilities post discharge (AOR = 1.07, 95% CI 0.88 to 1.33, p = .475) ( Table 2 ).

To the best of our knowledge, this report using a national administrative dataset from non-pandemic pre-COVID-19 era, is the largest and first description of While we did adjust for demographics (including age) and comorbidities in regression analysis, we cannot exclude the possibility of residual confounding.

Patients with CVD may have less ability to overcome stress of infections leading to worsening of respiratory status and related complications, which might have contributed to longer LOS and higher hospital charges. The mean total charges for the overall cohort were 1.55 billion USD, CVD subgroup leading to ~927 million USD.

Additionally, post discharge utilization of nursing home facilities was seen in a significant proportion of patients. Although our analysis is limited to non-pandemic setting and spans over hospitalizations over 2 years, it is reasonable to hypothesize that such charges will be multiple fold higher if analyzed during pandemic setting and after inclusion of cost of post discharge ancillary care services. Also the seasonal variability of viral infections including coronavirus family as seen in our study has been previously reported 33, 34 but interestingly the monthly proportion of patients with CVD and mortality remained high and did not change significantly with admission months in our study.

Several limitations merit consideration when interpreting our findings. This is a retrospective observational study from an administrative database with unavailability of detailed clinical, laboratory, echocardiographic and pharmacotherapeutic information.

Details about specific strain of coronavirus were not available. Given the diagnosis of coronavirus depends on the respiratory viral panels that might not be readily available across all healthcare systems, the cases captured in dataset might reflect only a proportion J o u r n a l P r e -p r o o f of cases from medical centers with accessibility and technical expertise 3 . Our analysis is predisposed to selection bias as plausibly sicker patients are more likely to be hospitalized and undergo respiratory viral panel testing. It is not possible to differentiate the complications from pre-existing comorbidities in NIS dataset. Plausibly older patients with CVD are more likely to be tested than younger non-comorbid counterparts.

However due to the nature of our dataset, we were not able to determine the testing rates and make such comparisons. The information related to initial clinical presentation, post discharge events and long-term outcomes are not available in dataset. As details about cause of death are not available, death might have occurred without identification of CVD events and hence results need to be interpreted with caution. We were not able to study the outcomes of CV patients at high risk for infection related hospitalizations such as those with left ventricular assist devices 35 . Nevertheless, our findings provide description of national US hospitalizations with a diagnosis of coronavirus from pre-COVID-19 era and demonstrate the association of CVD with worse outcomes and healthcare resource utilization in patients with coronavirus.

We found that in pre-COVID-19 era, CVD in hospitalizations with a diagnosis of coronavirus is associated with higher in-hospital mortality and a substantially higher healthcare resource burden. Further studies are needed to validate our findings in COVID-19 era and to determine the causes of the increased mortality and associated expenditures that we observed in this high-risk cohort of patients with CVD. Efforts can J o u r n a l P r e -p r o o f then be directed toward decreasing these events, reducing costs, and optimizing healthrelated outcomes. Atrial arrythmias  I471, I491, I480, I481, I481, I4811, I4819, I482,  I4820, I4821, I483, I484, I4891, I4892  Ventricular arrythmias  I470, I472, I492, I493, I4901, 

In subgroup analysis, CVD of acute MI, HF, myocarditis, pericardial diseases, sudden cardiac arrest and acute pulmonary embolism were present in 10

6%]), were present more often among patients with CVD (Table 1). The proportion of hospitalizations with CVD changed non-significantly when stratified by the admission month. (Figure 2B) The diagnosis of pneumonia

Coronaviruses: an overview of their replication and pathogenesis

Origin and evolution of pathogenic coronaviruses

Model 2: adjusted for age, sex, race and insurance. Model 3: adjusted for all covariates in model 2 and hypertension, hyperlipidemia, diabetes, obesity, coronary artery disease, congestive heart failure, cerebrovascular disease, chronic pulmonary disease, renal disease, cancer, liver disease, peripheral vascular disease, dementia, pulmonary circulation disorder, obesity. Model 4 adjusted for all covariates in model 3 plus pneumonia, shock, acute respiratory failure

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

USD 73

Adjusted Total Charges, mean (95% CI a )